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a b s t r a c t
Drug-related factors and parasite resistance have been implicated in the failure of pentava-
lent antimonials (Sbv) in the Indian subcontinent; however, little information is available
on host-related factors. Parasitologically conﬁrmed kala-azar patients, treatment naïve to
Sbv, were prospectively recruited at a referral hospital in Nepal and were treated under
supervision with 30 doses of quality-assured sodium stibogluconate (SSG) 20mg/kg/day
and followed for 12 months to assess cure. Analysis of risk factors for treatment fail-
ure was assessed in those receiving ≥25 doses and completing 12 months of follow-up.
One hundred and ninety-eight cases were treated with SSG and the overall cure rate was
77.3% (153/198). Of the 181 cases who received ≥25 doses, 12-month follow-up data were
obtained in 169, comprising 153 patients (90.5%)with deﬁnite cure and 16 (9.5%) treatmentontrol programme
epal
failures. In the ﬁnal logistic regression model, increased failure to SSG was signiﬁcantly
associated with fever for ≥12 weeks [odds ratio (OR) =7.4], living in districts bordering the
high SSG resistance zone in Bihar (OR=6.1), interruption of treatment (OR=4.3) and ambu-
latory treatment (OR=10.2). Early diagnosis and supervised treatment is of paramount
importance to prevent treatment failures within the control programme.
© 2009 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All. Introduction
Visceral leishmaniasis (VL), or kala-azar, is considered
o be one of the most neglected diseases,1 with 90% of the
stimated 500 000 annual cases occurring in ﬁve coun-
ries (India, Bangladesh, Sudan, Nepal and Brazil).2 Until
ecently, ﬁrst-line therapy for VL in all these countries
as pentavalent antimonials (Sbv).3 However, since the
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1990 s a sustained and progressive decline in cure rates
with Sbv has been reported from the Bihar state of India,4,5
and indications of similar trends were also observed in
Nepal.6 In contrast, Sbv therapy continues to be effective
in HIV-negative kala-azar patients in Bangladesh and East
Africa.7–9
Several factors have been implicated in the therapeu-
tic failure of Sbv, either drug-related, such as inadequate
or incomplete regimens10 or the use of substandard
preparations,11 or parasite- or host-related. Antimonial-
resistant parasites have been described among clinical
isolates from India and Nepal.12,13
ygiene. Published by Elsevier Ltd. All rights reserved.
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BeyondHIV status, there is limited information on host-
related determinants of treatment responsiveness in VL.
Leishmania/HIV co-infected patients have low cure rates
and almost all patients are known to relapse with any form
of treatment.14,15 Risk factors for mortality in VL patients
have been related to anaemia, severemalnutrition and long
duration of illness.16 A signiﬁcant association with treat-
ment failure was also seen in patients presenting with
a large spleen at presentation, reﬂecting more advanced
disease.17
Recently, new drugs have been proposed as ﬁrst-
line therapy for VL, namely miltefosine18,19 and
paromomycin.20 Also, the use of combination ther-
apy to protect drugs from emerging resistance has been
advocated.21 There is a need to update therapeutic
guidelines for control programmes in disease-endemic
countries, while at the same time lessons need to be drawn
from the Sbv era. Here we report the results of a prospec-
tive study on clinical determinants of therapeutic failure
with Sbv therapy in parasitologically proven kala-azar
patients recruited at a tertiary care centre in Nepal.
2. Materials and methods
2.1. Study site and patient recruitment
This prospective studywas conducted at the B.P. Koirala
Institute of Health Sciences (BPKIHS), a university hospi-
tal in the eastern region of Nepal, from January 2001 to
September 2003.
All patients suspected as having VL (fever ≥2 weeks
duration with clinical splenomegaly) were admitted for
a complete diagnostic work-up. Parasitologically proven
kala-azar cases who were treatment-naïve to Sbv therapy
were enrolled in the study after obtaining informed con-
sent.
2.2. Study procedures
Clinicoepidemiological information was recorded on a
case record form. Investigations included complete blood
count, chemistry, blood culture, urine analysis and chest
radiography. HIV serology testing22 using two different
rapid tests, namely TRI-DOT (J. Mitra & Co. Pvt. Ltd., New
Delhi, India) andDetermine (Abbot JapanCo., Tokyo, Japan),
was performedonly in thosepatientswho failed to respond
to sodium stibogluconate (SSG) therapy. Diagnosis of kala-
azar was made by Giemsa-stained bone marrow aspirate
or spleen aspirate (if bone marrow aspirate was negative)
demonstrating Leishman-Donovanbodies, and theparasite
density score was determined.23
All VL cases were treated with generic SSG (sodium
antimony gluconate; Albert David Ltd., Calcutta, India)
20mg/kg/day for 30 days. Each batch of SSG was qual-
ity checked by the International Dispensary Association
(Amsterdam, The Netherlands). Patients were proposed to
stay in hospital for the full duration of therapy. However,
those who were unable to stay for the full course were dis-
chargedafter an initial treatmentof 5–7days in thehospital
and were provided with extra vials to complete the full
course of therapy at the local health facility. A treatmentcal Medicine and Hygiene 104 (2010) 225–229
record cardwasmaintained,which also recordedany inter-
ruption of therapy. Clinical assessment to deﬁne outcome
was conducted at the end of therapy and at 3, 6 and 12
months after completion of therapy. Parasitological assess-
ment was repeated at the end of therapy and at 6 months
in all patients and at any time during follow-up if relapse
was clinically suspected.
Patients were followed up at BPKIHS or were actively
traced in their homes if they did not attend BPKIHS on the
appointment date. Treatment failure patients were treated
with second-line therapywith amphotericin B1mg/kg/day
for 14 days.
2.3. Data analysis
For the analysis of risk factors for failure of SSG, a
per-protocol perspective was adopted, i.e. only kala-azar
patients who received ≥25 doses of SSG were included in
the analysis. Those who died before Day 25 while being
treated with SSG were excluded from the analysis as their
death was most likely related to the disease severity with
complications such as bleeding or septicaemia. Also, those
for whom SSG therapy was switched to the second-line
drug amphotericin B owing to side effects were excluded,
as were cases that could not be followed up for 12 months
after therapy.
2.4. Case deﬁnitions
Initial curewas deﬁned as a kala-azar casewith absence
of fever andnegativeparasitologyat theendof SSG therapy.
A non-responderwas deﬁned as a kala-azar casewith posi-
tive parasitology after 30 days of SSG therapy. Deﬁnite cure
was deﬁned as a kala-azar case with negative parasitology
and no clinical signs of relapse at 12 months follow-up. A
relapse case was deﬁned as a kala-azar case with initial
cure but with reappearance of clinical symptoms and signs
with positive parasitology during the 12 months follow-
up. SSG treatment failure was deﬁned as a non-responder
or relapse case.
2.5. Statistical procedures
Univariate analysis was performed for all potential risk
factors by computing the odds ratio (OR) and 95% CI. Pear-
son’s2 testwas computedandall determinants associated
with therapeutic failure at a P-value of < 0.2 were included
in the logistic regression. The best model was selected by
backward elimination entry. All tests were two-tailed with
a signiﬁcance level of 0.05. Data were analysed with the
STATA software package (StataCorp LP, College Station, TX,
USA).
3. Results
A total of 301 clinically suspected VL patients presented
at BPKIHS during the study period, of which 224 (74.4%)
wereparasitologically conﬁrmedkala-azar cases (Figure1).
Eighteen of them had received SSG in the past and eight
hadcontraindications toSSG.Of the remaining198patients
started on SSG, 181 received ≥25 doses. Of the remaining




























sigure 1. Recruitment and outcome of kala-azar patients. SSG: sodium
tibogluconate; AmB: amphotericin B.
7 cases, 5 died during therapy, 2 defaulted and 10 were
witched to amphotericin B owing to SSG-related adverse
ffects. Complete 12-month follow-up was obtained in
69 patients: 153 patients (90.5%) with deﬁnite cure and
6 (9.5%) treatment failures, which consisted of 14 non-
esponses and 2 relapses, the latter at 7 months and 11
onths after completion of therapy. Therefore, the over-
ll cure rate on SSG was 77.3% (153/198), with a 2.5% death
ate (5/198), an 8.1% failure rate (16/198) and a 5.1% switch
o second-line drug during treatment (10/198), while 6.1%
12/198) were lost to follow-up.
Risk factor analysis was done on the 169 patients with
omplete follow-up. Themedian age in this cohortwas23.9
ears (interquartile range 12–35 years), 44.4%were female,
64 (97%) received the full 25 injections at the BPKIHS
ospital and 5 (3%) received the injections partly on an
utpatient basis. TheHIV statuswasnegative in all 16 treat-
ent failures. In the univariate analysis of the association
f demographic, clinical and laboratory factors with treat-
ent failure (Supplementary Table 1), there was a strong
nd signiﬁcant association of treatment failure with fever
f ≥12 weeks duration (OR=4.7) and with high parasite
ensity (grade >3) (OR=3.1). Living in a district bordering
he high antimony resistance zone in Bihar (district nos. 4,
to 12 in Figure 2) and treatment interruption showed a
trong association with treatment failure but of borderline
tatistical signiﬁcance. The duration of treatment interrup-al Medicine and Hygiene 104 (2010) 225–229 227
tion ranged from3days to5days.Risk factors for SSG failure
in the ﬁnal logistic regression model are shown in Table 1.
4. Discussion
This prospective cohort study demonstrated that the
cure rate in VL patients treated with SSG in Eastern Nepal
was90.5% in theper-protocol analysis (i.e.≥25dailydoses).
From an intention-to-treat perspective, SSG cure rates
were much lower (77.3%).
Prolonged fever, treatment interruption, ambulatory
treatment and living close to the Bihar high resistance
area were independent risk factors for treatment fail-
ure with SSG. No other demographic (e.g. age) or clinical
(e.g. nutritional status) determinants could be identiﬁed.
Prolonged fever can be considered as a proxy of disease
advancement and in treatment naïve patients implies a
long delay in seeking treatment, such has been noted in the
subcontinent.7,24 Access to VL care in these endemic coun-
tries is difﬁcult due to multiple factors: lack of knowledge
on VL and health-seeking behaviour in at-risk populations;
weakness of the peripheral-level health facilities, with VL
care being centralised; and excessive cost of treatment
despite free provision of diagnostic tests and drugs by the
national Kala-azar Control Programme inNepal.25 With the
launch of the VL elimination programme, efforts are being
made to decentralise VL care by introducing rapid diag-
nostic tests (rK39 dipstick) and oral miltefosine therapy
at the primary health centre level26 as well as adoption
of strategies for active case detection. Early diagnosis and
treatment would be beneﬁcial both at the individual level
by decreasing morbidity and mortality and at the commu-
nity level by decreasing disease transmission.27 Treatment
interruption was negatively associated with clinical out-
come. In themajority of cases these interruptionswere due
to running out of available stock of SSG at the hospital level.
In India, treatment interruptions have been described with
the newer and more expensive drugs such as miltefosine,
when sold over the counter, highlighting the need for free
and supervised provision of drugs.28
Ambulatory treatment, even if directly observed in
this study by healthcare providers, was still indepen-
dently associated with treatment failure. We hypothesise
that providers might not always have given the full dose
required or may have signed off treatment cards with-
out giving the actual dose. Decentralised treatment of VL
should be tightly supervised by the clinicians and pro-
grammes, and all patients should be counselled about the
importance of treatment adherence, as in DOTS (directly
observed treatment short-course) programmes for tuber-
culosis or antiretroviral therapy for AIDS. This is crucial not
only for SSG but also for other antileishmanial treatments
(e.g.miltefosine, paromomycin), aswidespread inadequate
use of drugs has been deeply incriminated in the rise of
SSG treatment failure rates in the neighbouring province
of Bihar. Strict control of drug delivery and prevention of
drug resistancewould also be facilitated by the use of short
combined treatments such as those currently being studied
in India.29
Increased risk of treatment failure in patients coming
from Nepalese districts close to the areas of Bihar where
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Figure 2. Map of kala-azar-endemic districts in south-eastern Nepal and antimon
of Health Sciences.
Table 1
Final logistic regression model of risk factors for sodium stibogluconate
failure in kala-azar patients from eastern Nepal
Variable Odds ratio (95% CI) P-value
Districts bordering Bihar high 6.08 (1.46–25.34) 0.013
resistance foci
Fever ≥12 weeks 7.38 (2.13–25.59) 0.002
Interruption of treatment 4.31 (1.03–18.06) 0.046
Ambulatory treatment 10.24 (1.25–84.16) 0.03
SSG treatment failure rates exceed 60% andwhere resistant
strains of Leishmania donovani have been isolated conﬁrms
previous ﬁndings.4,6,12 The intense cross-border migration
of populations between Nepal and Bihar, considered an
important risk factor for the spread of VL in this region,27
would also suggest a spread of resistant strains of L. dono-
vani from Bihar to Nepal.30
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